^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Colorectal Cancer
    Drug:balstilimab (AGEN2034) (PD1 inhibitor) +
    botensilimab (AGEN1181) (CTLA4 antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Agenus Inc. Press Release
    Title:

    Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer

    Published date:
    04/17/2023
    Excerpt:
    Agenus Inc...has been granted Fast Track Designation from the US Food and Drug Administration (FDA) for the investigation of the combination of botensilimab (AGEN1181) and balstilimab (AGEN2034). The designation is for patients with non-microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) metastatic colorectal cancer with no active liver involvement...